Sunshine Lake Pharma Secures NMPA Approval for Insulin Degludec Injection, Expanding Insulin Portfolio
Key Highlights for Investors
- Approval of Insulin Degludec Injection: Sunshine Lake Pharma Co., Ltd. has received formal marketing approval from the National Medical Products Administration (NMPA) for its independently developed Insulin Degludec Injection, available in both cartridge and prefilled pen formats.
- Portfolio Expansion: With this approval, the company’s insulin portfolio in China increases to six products, covering basal, prandial, and premixed insulin types, and spanning second- to fourth-generation products.
- Clinical Advantages: Insulin Degludec is a fourth-generation, ultra-long-acting basal insulin analogue with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, allowing for once-daily dosing and significant improvement in patient compliance and flexibility.
- Pipeline Progress: The company’s Insulin Degludec/Insulin Aspart combination is under marketing authorization review, and HEC-151 (a once-weekly ultra-long-acting insulin) has entered Phase I clinical trials.
- International Milestone: Sunshine Lake’s Insulin Glargine Injection has received an approval letter from the US FDA in April 2026, making it the first PRC company to commercialize an insulin glargine product in the US market.
- Strategic Implications: The company is advancing international registration for multiple insulin products and aims to expand its international footprint, market share, and brand influence.
Detailed Report
Sunshine Lake Pharma Co., Ltd. (Stock Code: 6887), a leading Chinese pharmaceutical company, announced the official marketing approval for its Insulin Degludec Injection from the National Medical Products Administration (NMPA). This approval covers both cartridge and prefilled pen specifications, specifically:
- Cartridge-type: Guoyaozhunzi S20260058
- Prefilled pen-type: Guoyaozhunzi S20260059
Drug Features and Clinical Significance
- Insulin Degludec Injection is a fourth-generation, long-acting basal insulin analogue with a unique molecular structure and mechanism of action.
- Key clinical benefits include:
- Half-life of ~25 hours, with duration of action exceeding 42 hours – covers all basal insulin needs with just a single daily injection.
- Smoother glucose-lowering profile, with blood glucose variability at roughly one-fourth that of insulin glargine and minimal plasma fluctuation after steady state is achieved.
- Statistically significant reduction in confirmed and nocturnal hypoglycemia compared to insulin glargine.
- Ultra-long-acting pharmacokinetics allow for flexible dosing times, further enhancing patient adherence and convenience.
Portfolio and Pipeline Development
This new approval strengthens Sunshine Lake’s position in the Chinese insulin market, bringing its locally approved insulin products to a total of six. The portfolio now includes second- to fourth-generation insulins tailored for basal, prandial, and premixed applications, offering comprehensive solutions for diabetic patients’ varying needs.
The company’s pipeline demonstrates continued innovation and expansion:
- The Insulin Degludec/Insulin Aspart combination product is under review for marketing authorization.
- HEC-151, an innovative, once-weekly, ultra-long-acting insulin, recently entered Phase I clinical trials.
- The company is developing a multi-tiered insulin product strategy, integrating daily, weekly, and combination formulations.
International Expansion and Strategic Significance
Sunshine Lake’s global ambitions are underscored by a major milestone: its self-developed Insulin Glargine Injection received an FDA approval letter in April 2026, making it the fourth insulin glargine product approved in the United States and the first from a PRC pharmaceutical company. This positions Sunshine Lake as a pioneer among Chinese firms in the US insulin market, potentially opening significant revenue streams and enhancing international reputation.
Looking ahead, the company is actively pursuing overseas registrations for other insulin products, including insulin aspart and insulin degludec. Management aims to strengthen Sunshine Lake’s international market share, operational capabilities, and brand influence, ultimately bringing PRC-developed insulins to diabetic patients worldwide.
Shareholder Impact and Price Sensitivity
- Regulatory Approval: The NMPA approval of a fourth-generation, ultra-long-acting insulin is a significant product milestone and demonstrates the company’s R&D and regulatory capabilities.
- Portfolio Strength: Expansion to six approved insulin products cements Sunshine Lake’s competitive position in China’s large and growing diabetes market.
- Pipeline Progress: Ongoing pipeline advancements signal future growth and potential market share gains.
- US FDA Approval: The breakthrough into the US market with the Insulin Glargine Injection represents a major potential driver for international revenues and brand value.
- Global Ambitions: Accelerated overseas registrations and expansion strategies could lead to further share price appreciation if successfully executed.
Executive Statement
The announcement was authorized by Dr. Zhang Yingjun, Chairman, and was made to keep investors informed of Sunshine Lake’s latest business developments.
Disclaimer
The information contained in this article is based on Sunshine Lake Pharma’s voluntary public disclosure and is intended for informational purposes only. This does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Investors should conduct their own due diligence or consult a financial advisor before making any investment decisions. The company expressly disclaims any liability for investment decisions made based on this information.
